Epilepsy Ireland’s 10th Annual All Cash Mega Raffle is officially open!
Tickets for the raffle cost only €3 and you could be in with a chance of winning €2,000, €1,000 or €500 when the big draw takes place on November 15th.
Further to our most recent update regarding Gabitril supply in Ireland, Gabitril’s manufacturer TEVA have been in touch to confirm that the measure regarding the extension of shelf-life for 10mg & 15mg tablets has been accepted by the HPRA.
New research from the Korea Brain Institute has identified the structure and mechanism of a membrane protein which can cause epilepsy.
Membrane proteins are the gatekeepers to the cell and are essential to the function of all cells. They control the flow of information or messages between cells.
The UK’s National Institute for Health and Care Excellence (NICE) has announced that it would not recommend Epidyolex (cannabidiol) combined with clobazam (Frisium) for the treatment of Lennox-Gastaut syndrome and Dravet syndrome.
New research from the Ann & Robert H Lurie Children’s Hospital of Chicago has found that young children with epilepsy caused by genetic abnormality had a better response to the ketogenic diet compared to children with other types of epilepsy.
The ketogenic diet is a low carbohydrate, high fat diet that is used to treat epilepsy which has not responded to other treatments. More information on this can be found here.
A shortage of Gabitril (5, 10 & 15mg) film coated tablets has been confirmed by the Health Products Regulation Authority with manufacturing delays cited as the reason for the shortage.
The HPRA have stated that the expected return date of normal supply is October 2019.
Epilepsy Ireland contacted both the HPRA and the manufacturers of Gabitril-TEVA-seeking further information on the shortage.
A new genomics module in the Irish National Epilepsy Electronic Patient Record has been developed by researchers in FutureNeuro & the HSE Epilepsy Lighthouse Project.
The new research was published in the latest issue of the journal Epilepsia; the leading source for clinical research on epilepsy.
Two reports recently published in the UK regarding the use of cannabis based products for a number of medical conditions have pointed to the need for further clinical evidence & research regarding their use to treat severe treatment-resistant epilepsy.
We are delighted to confirm that our application under the Scheme to Support National Organisations in the Community and Voluntary Sector 2019-2022 has been successful.